Q2 2024 EPS Estimates for Encompass Health Co. (NYSE:EHC) Cut by William Blair

Encompass Health Co. (NYSE:EHC) – Investment analysts at William Blair dropped their Q2 2024 earnings per share (EPS) estimates for shares of Encompass Health in a research report issued to clients and investors on Wednesday, April 24th. William Blair analyst J. Haase now expects that the company will post earnings per share of $0.96 for the quarter, down from their previous estimate of $0.97. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Encompass Health’s current full-year earnings is $3.96 per share. William Blair also issued estimates for Encompass Health’s Q3 2024 earnings at $0.94 EPS, Q4 2024 earnings at $0.99 EPS, FY2024 earnings at $4.01 EPS, Q3 2025 earnings at $1.07 EPS, Q4 2025 earnings at $1.13 EPS and FY2025 earnings at $4.58 EPS.

Encompass Health (NYSE:EHC) last announced its earnings results on Wednesday, April 24th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.93 by $0.19. The firm had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.27 billion. Encompass Health had a return on equity of 18.48% and a net margin of 7.60%. The business’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.88 EPS.

A number of other brokerages also recently issued reports on EHC. Truist Financial boosted their price objective on Encompass Health from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Friday, February 9th. Stephens reaffirmed an “overweight” rating and issued a $85.00 target price on shares of Encompass Health in a report on Tuesday, January 16th. Royal Bank of Canada reiterated an “outperform” rating and issued a $83.00 price objective on shares of Encompass Health in a research note on Friday, February 9th. Barclays increased their target price on Encompass Health from $101.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Mizuho increased their price objective on Encompass Health from $93.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $85.44.

Encompass Health Stock Down 0.1 %

Shares of EHC opened at $82.74 on Friday. The company has a market capitalization of $8.29 billion, a PE ratio of 22.36, a PEG ratio of 1.53 and a beta of 0.94. The company has a current ratio of 1.28, a quick ratio of 1.28 and a debt-to-equity ratio of 1.19. The stock’s 50-day moving average price is $78.07 and its two-hundred day moving average price is $70.76. Encompass Health has a 12 month low of $57.55 and a 12 month high of $85.84.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Monday, April 1st were issued a dividend of $0.15 per share. The ex-dividend date of this dividend was Thursday, March 28th. This represents a $0.60 annualized dividend and a dividend yield of 0.73%. Encompass Health’s payout ratio is 16.22%.

Hedge Funds Weigh In On Encompass Health

Large investors have recently made changes to their positions in the business. AE Wealth Management LLC increased its position in shares of Encompass Health by 26.8% during the third quarter. AE Wealth Management LLC now owns 6,381 shares of the company’s stock valued at $429,000 after acquiring an additional 1,350 shares in the last quarter. Oak Thistle LLC bought a new stake in shares of Encompass Health during the third quarter valued at approximately $814,000. Linden Thomas Advisory Services LLC grew its position in Encompass Health by 22.1% in the 3rd quarter. Linden Thomas Advisory Services LLC now owns 15,220 shares of the company’s stock worth $1,022,000 after purchasing an additional 2,754 shares during the period. Copeland Capital Management LLC grew its position in Encompass Health by 0.5% in the 3rd quarter. Copeland Capital Management LLC now owns 1,277,690 shares of the company’s stock worth $85,810,000 after purchasing an additional 6,009 shares during the period. Finally, Tectonic Advisors LLC bought a new stake in Encompass Health in the 3rd quarter worth approximately $343,000. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.